Product Center
HRK-X has been selected for the 2024 Jiangsu Province Innovative Pharmaceutical Equipment Special Award List!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-03-08
- Views:
(Summary description)Recently, the list of innovative drug and device award projects of the special fund for the construction of a strong manufacturing province in Jiangsu Province in 2024 was released, Ab&B Bio-Tech CO.,LTD. JS's self-developed quadrivalent influenza virus subunit vaccine (HRK-X), a new class of drugs, was selected into the list of approved innovative drugs in 2023.
HRK-X has been selected for the 2024 Jiangsu Province Innovative Pharmaceutical Equipment Special Award List!
(Summary description)Recently, the list of innovative drug and device award projects of the special fund for the construction of a strong manufacturing province in Jiangsu Province in 2024 was released, Ab&B Bio-Tech CO.,LTD. JS's self-developed quadrivalent influenza virus subunit vaccine (HRK-X), a new class of drugs, was selected into the list of approved innovative drugs in 2023.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-03-08 16:20
- Views:
Recently, the list of innovative drug and device award projects of the special fund for the construction of a strong manufacturing province in Jiangsu Province in 2024 was released, Ab&B Bio-Tech CO.,LTD. JS's self-developed quadrivalent influenza virus subunit vaccine (HRK-X), a new class of drugs, was selected into the list of approved innovative drugs in 2023.
As a class 1 new drug of biological products for prevention, HRK-X has its unique influenza virus subunit extraction process technology, which not only ensures the high purity of HA and NA of the four vaccine strains and the safety of the vaccine, but also shows good immunogenicity, and the quality standards of the products are higher than the standards of the Chinese and EU Pharmacopoeia, filling the domestic gap!
Recently, the Pharmaceutical High tech Zone (Gaogang District) awarded An Youcai, Chairman and General Manager of Ab&B Bio-Tech CO.,LTD, the honorary title of "Top Ten Star Entrepreneurs" at the conference to promote entrepreneurial spirit and promote new industrialization! We fully recognize the spirit of Mr. An and Ab&B Bio in the development and industrialization of innovative vaccines for human use, which are daring to take risks and pioneering!
Relevant information
-
Breaking through bottleneck technology, significant progress has been made in the research and development of new adjuvantsOn August 25th, the R&D team of Yither Biotech (Shanghai) Co., Ltd, a wholly-owned subsidiary of Ab&B Bio Tech Co., Ltd (locally referred to as "Zhonghui Bio"), made a breakthrough in the field of innovative adjuvant research and development. The research results were published online in the internationally renowned journal "Journal of Drug Delivery Science and Technology" under the title "Dual functional Emulsifier Based Nano Emulsification Adjuvant Effectively Enhanced Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine in Mice". - Obtained recognition as one of the first offshore innovation centers for enterprises in Taizhou 08-14
- Recombinant herpes zoster vaccine (CHO cells) IND application approved 08-13
- IND application for quadrivalent influenza virus subunit vaccine (adjuvant) approved 07-30
- World Influenza Conference 2024 | Decoding new possibilities for the future of influenza vaccines 07-09
Have a project？Get a touch!
Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio
Contact
E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
